Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
Novo Nordisk A/S
Study ID
NCT01511185
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    A single dose of 7.5 mcg/kg administered subcutaneously in random order
  • placebo — DRUG
    A single dose administered subcutaneously in random order

Study Details

This trial is conducted in the United States of America (USA). The aim of this trial is to assess the effect of NNC 90-1170 on beta-cell responsiveness to increasing blood glucose concentrations in subjects with type 2 diabetes.

Key Dates

Start date
Feb 28, 2001
Status verified
Jan 2017
Primary completion
Oct 31, 2001
Completion
Oct 31, 2001

Study Design

Enrollment
20 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: NNC 90-1170
  • Placebo Comparator: Placebo
  • No Intervention: Healthy

Primary Outcome Measure

AUC (area under the curve) of Insulin Secretion Rate (ISR) over the 90-216 mg/dL glucose interval

Locations (1)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SiteAnn ArborMichigan48109-0926-

Find similar trials in Ann Arbor, MI

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Ann Arbor, MI

Related Studies